Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Viridian Therapeutics Inc (NQ: VRDN ) 24.25 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Viridian Therapeutics Inc < Previous 1 2 3 4 Next > Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics September 26, 2024 Via Benzinga Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know September 10, 2024 Via Benzinga Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday September 10, 2024 Via Benzinga Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival September 10, 2024 The results are also promising for the next-generation version of that drug. Via Investor's Business Daily Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety September 10, 2024 Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans... Via Benzinga Exposures Product Safety Decoding 6 Analyst Evaluations For Viridian Therapeutics August 15, 2024 Via Benzinga Expert Ratings For Viridian Therapeutics July 16, 2024 Via Benzinga 7 Analysts Assess Viridian Therapeutics: What You Need To Know June 06, 2024 Via Benzinga Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket September 10, 2024 Via Benzinga VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024 August 08, 2024 VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Top 3 Health Care Stocks You May Want To Dump This Quarter July 30, 2024 Via Benzinga Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense July 16, 2024 Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. Via Investor's Business Daily 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. Via InvestorPlace Unveiling 4 Analyst Insights On Viridian Therapeutics March 20, 2024 Via Benzinga Navigating 6 Analyst Ratings For Viridian Therapeutics February 28, 2024 Via Benzinga Analyst Ratings for Viridian Therapeutics December 04, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 11, 2024 Via Benzinga VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20 March 19, 2024 Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them. Via InvestorPlace Here's Why Viridian Therapeutics (VRDN) Stock Is Moving January 18, 2024 Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering. Via Benzinga ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday December 18, 2023 U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday. Via Benzinga Topics Stocks Exposures US Equities Where Viridian Therapeutics Stands With Analysts November 14, 2023 Via Benzinga Analyst Ratings for Viridian Therapeutics September 13, 2023 Via Benzinga Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday October 30, 2023 U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities Stocks That Hit 52-Week Lows On Tuesday October 03, 2023 On Tuesday, 647 companies set new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Thursday September 28, 2023 During Thursday's session, 406 companies made new 52-week lows. Via Benzinga 9 Analysts Have This to Say About Viridian Therapeutics August 09, 2023 Via Benzinga Stocks That Hit 52-Week Lows On Tuesday September 26, 2023 On Tuesday, 386 stocks made new 52-week lows. Via Benzinga Stocks That Hit 52-Week Lows On Thursday September 21, 2023 During the session on Thursday, 461 stocks hit new 52-week lows. Via Benzinga Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday August 10, 2023 Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.